Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682485 | 1.00 | PDE5A (0.65) | PDE5A | |
| SCHEMBL21682601 | 1.00 | PDE5A (0.65) | PDE5A | |
| SCHEMBL21682483 | 1.00 | PDE5A (0.65) | PDE5A | |
| SCHEMBL21682583 | 0.93 | PDE5A (0.66) | PDE5A | |
| SCHEMBL21705400 | 0.93 | PDE5A (0.66) | PDE5A | |
| SCHEMBL21682579 | 0.93 | PDE5A (0.66) | PDE5A | |
| SCHEMBL31028931 | 0.93 | PDE5A (0.66) | PDE5A | |
| SCHEMBL21682525 | 0.92 | PDE5A (0.71) | PDE5A | |
| SCHEMBL21682603 | 0.92 | PDE5A (0.71) | PDE5A | |
| SCHEMBL31028965 | 0.92 | PDE5A (0.71) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4236952-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | Nicox S.A. (FR) | 2023-09-06 | — | — | EP | claimed |
| WO-2022090379-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2022-05-05 | — | — | WO | claimed |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | disclosed |
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | disclosed |
| EP-4236952-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | Nicox S.A. (FR) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022090379-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE3A, PDE6A | PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.